Abstract
Background Left frontal alpha oscillations are associated with decreased approach motivation and have been proposed as a target for non-invasive brain stimulation for the treatment of depression and anhedonia. Indeed, transcranial alternating current stimulation (tACS) at the alpha frequency reduced left frontal alpha power and was associated with a higher response rate than placebo stimulation in patients with major depressive disorder (MDD) in a recent double-blind placebo controlled clinical trial.
Methods In this current study, we aimed to replicate such successful target engagement by delineating the effects of a single session of bifrontal tACS at the individualized alpha frequency (IAF-tACS) on alpha oscillations in patients with MDD. Electrical brain activity was recorded during rest and while viewing emotionally-salient images before and after stimulation to investigate if the modulation of alpha oscillation by tACS exhibited specificity with regards to valence.
Results In agreement with the previous study of tACS in MDD, we found that a single session of bifrontal IAF-tACS reduced left frontal alpha power during the resting state when compared to placebo. Furthermore, the reduction of left frontal alpha oscillation by tACS was specific for stimuli with positive valence. In contrast, these effects on left frontal alpha power were not found in healthy control participants.
Conclusion Together these results support an important role of tACS in reducing left frontal alpha oscillations as a future treatment for MDD.
National Clinical Trial NCT03449979, “Single Session of tACS in a Depressive Episode (SSDE)” https://www.clinicaltrials.gov/ct2/show/NCT03449979
Competing Interest Statement
FF is the lead inventor of IP filed by UNC. Flavio Frohlich is founder, shareholder, and chief science officer of Pulvinar Neuro, which did not play any role in the writing of this article. FF has received honoraria from the following entities in the last twelve months: Sage Therapeutics, Academic Press, Insel Spital, and Strategic Innovation. JR, MLA, CES, and DRR have no conflict of interest.
Clinical Trial
NCT03449979
Funding Statement
This study was supported in part by the National Institute of Mental Health of the National Institutes of Health under Award Numbers R01MH101547 and R01MH111889 awarded to FF and the postdoctoral training program (JR) in reproductive mood disorders T32MH09331502 awarded to DR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB from the University of North Carolina at Chapel Hill
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data is available upon request.
